TL;DR
Get workout gear delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
A September 29 endocrinology roundup reported that the FDA gave Vitruvias Therapeutics’ recall of one lot of 30-mg thyroid tablets its Class I classification, the agency’s most serious recall category. The roundup also cited a study finding nutritional deficiencies in nearly 17% of adolescents taking GLP-1 drugs within a year and updated joint guidance for managing type 1 diabetes in adults.
A September 29 endocrinology roundup reported that the FDA classified Vitruvias Therapeutics’ recall of one lot of 30-mg levothyroxine-liothyronine tablets as Class I, its most serious recall category. The roundup also highlighted a study reporting nutritional deficiencies among adolescents taking GLP-1 drugs and updated joint guidance from the American Diabetes Association and the European Association for the Study of Diabetes for adults with type 1 diabetes.
The FDA classification applies to a recall involving one lot of 30-mg thyroid tablets made by Vitruvias Therapeutics, according to the roundup, which cited USA Today. Class I is the agency’s most serious recall classification. The source material does not identify the lot number, explain the specific defect or risk, or say how many tablets were distributed. Those details are needed for patients and clinicians to determine whether a particular prescription is affected.
A separate study, cited as published in Childhood Obesity, found that nearly 17% of adolescents taking a GLP-1 drug were diagnosed with at least one nutritional deficiency within the first year after starting treatment. Vitamin D deficiency was the most frequently reported. The roundup does not provide the study’s participant count, the drugs examined, or a comparison with adolescents not taking these medicines, so the result describes the study group and does not establish that the drugs caused the deficiencies.
The American Diabetes Association and EASD also issued updated joint consensus guidelines for managing type 1 diabetes in adults, according to the roundup, which cited Diabetes Care. It did not summarize the recommendations or explain how they differ from prior guidance. Other items included Roche’s decision to halt development of the investigational muscle-building drug emugrobart after a disappointing interim analysis in a phase II study, and a phase II trial report from Viking Therapeutics on less frequent dosing of its investigational obesity drug.
Recall and Treatment Questions for Patients
The Class I designation makes the thyroid tablet recall a direct medication-safety concern for people who may have received the affected lot. Because the supplied report does not list the lot number or describe the recall reason, patients cannot use this roundup alone to check whether their own supply is involved. The classification is a signal to seek the recall notice and verify the product details with a pharmacist or clinician.
The adolescent findings add a monitoring question to ongoing GLP-1 use. A report that nearly one in six adolescents in the study had at least one diagnosed deficiency could be relevant to families and prescribers, particularly given the frequency of vitamin D deficiency in the results. But the available summary does not establish causation or show whether the rate exceeded a comparison group. The findings warrant attention as study results, not a conclusion that GLP-1 medicines cause nutritional deficiencies.
The updated adult type 1 diabetes guidance may affect clinical practice, but the roundup gives no recommendation-level detail. Clinicians and patients will need the full guideline to understand what has changed and which care decisions it addresses. Together, the items span a recall notice, emerging treatment evidence and practice guidance, each of which requires its own source and level of scrutiny.
Products Worth Considering
Therabody Theragun Prime 6th Generation Deep Tissue Massage Gun, Navy
Garmin Forerunner 165 GPS Running Smartwatch, 43 mm, Black
Bowflex SelectTech 840 Adjustable Kettlebell
As an affiliate, we earn on qualifying purchases.
Three Developments in Endocrinology
The developments appeared in a news-and-commentary roundup published by MedPage Today on September 29, 2026. Its items drew on reports and publications from several sources, including USA Today, Diabetes Care and Childhood Obesity. The roundup format places distinct developments together; it does not indicate that the recall, adolescent study and diabetes guidance are related.
The GLP-1 coverage also included several company-reported or meeting-presented comparisons. Eli Lilly said tirzepatide (Zepbound) produced greater weight loss than semaglutide (Wegovy HD) in an indirect comparison of trials presented at the EASD annual meeting. Lilly also reported indirect comparisons in adults with type 2 diabetes that favored its oral GLP-1 drug orforglipron (Foundayo) over oral semaglutide (Rybelsus) for weight loss and HbA1c reduction. Novo Nordisk, by contrast, said adults with type 2 diabetes who doubled their semaglutide (Ozempic) dose had a lower risk of major adverse cardiovascular events than those switching to tirzepatide (Mounjaro). These were not described as direct head-to-head trials.
Other items covered a preprint suggesting that weight patterns before GLP-1 treatment may predict a strong response, and a study finding that Berkeley’s healthy-checkout ordinance was associated with lower soda sales but not candy sales. The evidence types vary, from a preprint and quasi-experimental research to company announcements; the roundup’s brief summaries do not provide enough detail to assess methods or compare results.
“Updated joint consensus guidelines for managing type 1 diabetes in adults.”
— American Diabetes Association and European Association for the Study of Diabetes, as summarized by MedPage Today
Lot Details and Study Limits
The roundup does not state the recalled lot number, distribution area, recall cause or reported harm. It also does not say whether the FDA or manufacturer issued additional instructions for patients. The summary alone cannot establish whether a specific prescription is affected.
For the adolescent GLP-1 study, key information is absent from the roundup, including the number and characteristics of participants, the specific medicines studied, and whether researchers compared results with a control group. The reported deficiency diagnoses do not by themselves show that treatment caused them. The preprint on weight trajectories is also preliminary evidence, as described in the source.
The joint adult type 1 diabetes guidelines are not detailed in the supplied material, leaving their recommendations and clinical scope unclear. The indirect drug comparisons and company statements likewise do not establish how the medicines would compare in a direct trial.
Check Notices and Full Publications
Patients taking the recalled thyroid tablets can check the FDA or manufacturer recall notice for the affected lot and contact a pharmacist or prescriber if their supply may match. The roundup does not provide a deadline or specific remedy, so those details should be confirmed in the notice itself.
For the GLP-1 findings, the next step for readers seeking the full evidence is to consult the study in Childhood Obesity for its methods and limitations. Clinicians and patients can review the ADA-EASD publication in Diabetes Care for the actual adult type 1 diabetes recommendations. Further detail on the ongoing drug studies and comparisons may emerge through full publications, trial updates or subsequent meeting reports.
Key Questions
Which thyroid medicine was recalled?
The roundup identifies a recall by Vitruvias Therapeutics involving one lot of 30-mg levothyroxine-liothyronine tablets, referred to as Thyroid Tablets. It does not provide the lot number.
What does the Class I classification mean in this report?
The roundup describes Class I as the FDA’s most serious recall classification. It does not include the specific reason for the classification or the risk associated with the affected lot.
Did the adolescent study show GLP-1 drugs caused deficiencies?
No causal conclusion is provided in the roundup. It says nearly 17% of adolescents taking a GLP-1 drug were diagnosed with at least one nutritional deficiency within a year; vitamin D deficiency was most frequent. The summary does not provide the comparison basis or study methods.
What changed in the adult type 1 diabetes guidance?
The ADA and EASD issued updated joint consensus guidelines, but the roundup does not describe the recommendations or how they differ from previous guidance. The full publication in Diabetes Care is needed for those details.
Source: rss
